ImmunoGen, Inc.

ImmunoGen, Inc. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
1981-01-01
Employees
501
Market Cap
-
Website
http://www.immunogen.com

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

First Posted Date
2022-09-02
Last Posted Date
2024-11-27
Lead Sponsor
ImmunoGen, Inc.
Target Recruit Count
423
Registration Number
NCT05527184
Locations
🇺🇸

Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

🇺🇸

University of Colorado Anschutz Cancer Pavilion, Aurora, Colorado, United States

🇺🇸

Florida Cancer Specialists, Sarasota, Florida, United States

and more 6 locations

First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-11-10
Last Posted Date
2024-03-15
Lead Sponsor
ImmunoGen, Inc.
Target Recruit Count
56
Registration Number
NCT04622774
Locations
🇺🇸

Washington University, Saint Louis, Missouri, United States

🇮🇹

Policlinico di Modena, Modena, Italy

🇮🇹

Azienda Ospedaliera Universitaria Senese, Siena, Italy

and more 10 locations

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

First Posted Date
2020-03-05
Last Posted Date
2024-08-07
Lead Sponsor
ImmunoGen, Inc.
Target Recruit Count
106
Registration Number
NCT04296890
Locations
🇺🇸

St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States

🇦🇺

St John of God Subiaco Hospital, Subiaco, Western Australia, Australia

🇮🇱

Shaare Zedek Medical Center, Jerusalem, Israel

and more 86 locations

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

First Posted Date
2019-12-24
Last Posted Date
2024-11-19
Lead Sponsor
ImmunoGen, Inc.
Target Recruit Count
453
Registration Number
NCT04209855
Locations
🇺🇸

Illinois Cancer Specialists, Arlington Heights, Illinois, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

and more 210 locations

Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-02-04
Last Posted Date
2019-09-04
Lead Sponsor
ImmunoGen, Inc.
Target Recruit Count
62
Registration Number
NCT02674763
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Baylor Scott & White University Medical Center, Dallas, Texas, United States

🇺🇸

The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

and more 4 locations

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

First Posted Date
2015-12-16
Last Posted Date
2020-10-14
Lead Sponsor
ImmunoGen, Inc.
Target Recruit Count
366
Registration Number
NCT02631876
Locations
🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

🇺🇸

Georgia Regents University (GRU)-Medical College of Georgia (MCG) - Cancer Center, Augusta, Georgia, United States

🇺🇸

UCLA Women's Health Clinical Research Unit - OBGYN, Los Angeles, California, United States

and more 128 locations

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

First Posted Date
2015-11-17
Last Posted Date
2024-06-14
Lead Sponsor
ImmunoGen, Inc.
Target Recruit Count
264
Registration Number
NCT02606305
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇧🇪

Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg - Leuvens Kankerinstituut, Leuven, Belgium

🇺🇸

The Ohio State University, Hilliard, Ohio, United States

and more 9 locations

A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2013-10-16
Last Posted Date
2015-10-02
Lead Sponsor
ImmunoGen, Inc.
Target Recruit Count
20
Registration Number
NCT01963715
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Karmanos Cancer Institute, Detroit, Michigan, United States

and more 1 locations

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-06-01
Last Posted Date
2021-02-17
Lead Sponsor
ImmunoGen, Inc.
Target Recruit Count
206
Registration Number
NCT01609556
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 9 locations

IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

First Posted Date
2012-02-17
Last Posted Date
2017-12-29
Lead Sponsor
ImmunoGen, Inc.
Target Recruit Count
49
Registration Number
NCT01534715
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

Medical College of Wisconsin, Milwaukee, Wisconsin, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 4 locations
© Copyright 2024. All Rights Reserved by MedPath